Replimune Group, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Replimune Group, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2016 to 2023.
  • Replimune Group, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending June 30, 2024 was $96.6M, a 8645% increase year-over-year.
  • Replimune Group, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $16.3M, a 94.8% decline from 2022.
  • Replimune Group, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $311M, a 4618% increase from 2021.
  • Replimune Group, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $6.6M, a 98.2% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $16.3M -$295M -94.8% Apr 1, 2023 Mar 31, 2024 10-K 2024-05-16
2022 $311M +$305M +4618% Apr 1, 2022 Mar 31, 2023 10-K 2024-05-16
2021 $6.6M -$366M -98.2% Apr 1, 2021 Mar 31, 2022 10-K 2023-05-18
2020 $372M +$272M +272% Apr 1, 2020 Mar 31, 2021 10-K 2022-05-19
2019 $100M -$1.22M -1.21% Apr 1, 2019 Mar 31, 2020 10-K 2021-05-20
2018 $101M +$46.6M +85.2% Apr 1, 2018 Mar 31, 2019 10-K 2020-06-03
2017 $54.8M +$39.8M +265% Apr 1, 2017 Mar 31, 2018 10-K 2020-06-03
2016 $15M Apr 1, 2016 Mar 31, 2017 10-K 2019-06-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.